There is no effective treatment for fibrolamellar liver cancer that cannot be removed surgically. In this study, researchers are evaluating different combinations of the drugs everolimus, letrozole, and leuprolide to treat patients with inoperable fibrolamellar liver cancer.
Leuprolide and letrozole inhibit the production of the hormone estrogen, which can fuel the growth of fibrolamellar liver cancer. Everolimus works by inhibiting mTOR, a protein that drives cancer growth.
In this study, patients will be randomly assigned to one of three treatment groups: (1) everolimus alone, (2) leuprolide and letrozole, or (3) everolimus, leuprolide, and letrozole. Patients in groups 1 and 2 who do not do well on those regimens have the option of receiving all three drugs together.